Editing Bausch & Lomb (section)

==Business areas==
[[Image:Bausch & Lomb Vision Care campus.JPG|thumb|right|The Global Eye Health Center in [[Rochester, New York]]]]
Business areas are divided into three large divisions:
* Vision Care: contact lenses and eye-care products.
* Pharmaceuticals: medicines for various eye diseases and irritations.
* Surgery: aids and implants.

In the last few years, several business areas in the Vision Care division have been developed in the framework of product diversification. The manufacturing of contact lenses still accounted for 28% of Bausch & Lomb's turnover in 2001, making it its main business activity. The "SofLens One Day" [[soft contact lens]] range have to be changed every day. The product assortment includes higher quality lenses, such as the "SofLens Comfort" or "Seequence" lenses which can be changed after two weeks. The "SofLens66 Toric" were specially designed for people with [[Astigmatism (eye)|astigmatism]]. Lenses from the "Boston" range have a higher oxygen permeability and are more suited for people with sensitive or dry eyes. The newest and most advanced lens range is called "PureVision".<ref>{{Cite journal|last1=Lim|first1=L.|last2=Tan|first2=D. T.|last3=Chan|first3=W. K.|title=Therapeutic use of Bausch & Lomb PureVision contact lenses|url=https://pubmed.ncbi.nlm.nih.gov/11725978/|journal=The CLAO Journal |year=2001|volume=27|issue=4|pages=179–185|issn=0733-8902|pmid=11725978}}</ref> These lenses are so oxygen-permeable that they can remain in the eye up to 30 days without being taken out at night. The second largest business, at 25%, is the manufacture of lens-care products. As well as simple combination cleaning and disinfectant solutions for both soft and hard lenses, pH neutral solutions are available for people with particularly sensitive eyes.

The Pharmaceuticals division manufactures pharmaceutical eye products, which account for 21% of turnover. This range covers prescription medicines for eye irritation, allergic reactions or high eye pressure. The development of this division was speeded up by take-overs of other firms.

The Surgicals division is divided into Refractive Surgery with 8% of turnover and Cataract Vitreotinal Surgery with 18%. The latter division is concerned with products for operations on glaucoma and cataracts and on the cornea, as well as implantable, interocular lenses. The Refractive Surgery division comprises mainly medical analysis devices and lasers required for eye surgery. In order to strengthen this division, the competing companies of Storz and Chiron were acquired.

===PureVision===
Bausch + Lomb was in a lawsuit with [[Novartis]] which claimed to have [[patent]]s on a Bausch + Lomb product called PureVision. On June 26, 2002, a federal judge ruled that Bausch & Lomb did infringe on [[Ciba Vision]] (a subsidiary of Alcon) patents.<ref name="NYTimes">{{cite news
  | title =  Company News: Bausch + Lomb is found guilty of patent infringement
  | date = 2002-07-27
  | work = [[The New York Times]]
  | url = https://query.nytimes.com/gst/fullpage.html?res=9E04E6DD123EF934A15755C0A9649C8B63&n=Top%2fNews%2fScience%2fTopics%2fInventions%20and%20Patents
  | access-date = 2007-04-19
}}</ref>

On July 2, 2004, the company announced that it had licensed the intellectual property of Novartis.<ref name="Settlement">{{cite news
 |title=Bausch & Lomb, Ciba Vision reach settlement of patent litigation
 |url=http://findarticles.com/p/articles/mi_qn4180/is_20040707/ai_n10070038
 |archive-url=https://web.archive.org/web/20090220065342/http://findarticles.com/p/articles/mi_qn4180/is_20040707/ai_n10070038
 |url-status=dead
 |archive-date=2009-02-20
 |date=2004-07-07
 |access-date=2007-04-19
 |publisher=The Daily Record (Rochester, New York)
}}</ref> Bausch & Lomb will pay the Ciba Vision unit of Novartis a royalty on net U.S. sales of its PureVision brand contact lenses until 2014 and on net sales outside the U.S. until 2016. But as of now, the brand FreshLook comes under Bausch and Lomb and Ciba manufacturers it.

===ReNu product recalls===
:{{main|ReNu}}
On April 11, 2006, Bausch & Lomb stopped shipments of its [[ReNu]] with MoistureLoc contact lens solution when the [[Centers for Disease Control and Prevention]] (CDC) announced there was a high correlation between use of the product and cases of suspected fungal [[keratitis]].<ref name="CDC">{{cite news
  | url = https://www.cdc.gov/mmwr/preview/mmwrhtml/mm5514a5.htm
  | title = Fusarium Keratitis — Multiple States, 2006
  | date = 2006-04-14
  | access-date = 2007-04-19
| archive-url= https://web.archive.org/web/20070517012610/http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5514a5.htm| archive-date= 17 May 2007 <!--DASHBot-->| url-status=live}}</ref> The [[Centers for Disease Control]] found that "nearly all of the company's ReNu with MoistureLoc eye care products were linked to severe fungal eye infections".<ref name="ForbesReNu">{{cite news
  | url = https://www.forbes.com/markets/2006/05/03/bauschandlomb-recalls-0503markets03.html
  | archive-url = https://web.archive.org/web/20071116032703/http://www.forbes.com/markets/2006/05/03/bauschandlomb-recalls-0503markets03.html
  | url-status = dead
  | archive-date = November 16, 2007
  | date = 2006-05-03
  | access-date = 2007-04-19
  | title = More Recalls Ahead For Bausch & Lomb?
  | first = Mary
  | last = Crane
| work=Forbes
}}</ref> Two class action lawsuits have been filed against Bausch & Lomb in relation to the eye fungus problems.<ref name="CBC Lawsuits">{{cite news
  | url = https://www.cbsnews.com/news/eye-fungus-lawsuits-filed/
  | title = Eye Fungus Lawsuits Filed: Bausch & Lomb Could Face Class Action Suit Over Lens Solution
  | agency = Associated Press
  | date = 2006-04-20
  | access-date = 2007-04-19
}}</ref>

===Diversity===
Bausch & Lomb received a 100% rating on the [[Corporate Equality Index]] released by the [[Human Rights Campaign]] starting in 2003, the second year of the report.<ref name="CEI">{{cite web
 |url=http://www.hrc.org/Template.cfm?Section=About_HRC&Template=/ContentManagement/ContentDisplay.cfm&ContentID=15282
 |title=Corporate Equality Index (2003)
 |publisher=[[Human Rights Campaign]] Foundation
 |year=2003
 |access-date=2007-04-19
 |url-status=dead
 |archive-url=https://web.archive.org/web/20070930031325/http://www.hrc.org/Template.cfm?Section=About_HRC&Template=%2FContentManagement%2FContentDisplay.cfm&ContentID=15282
 |archive-date=2007-09-30
}}</ref>